Research & Literature

Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee.

Fang JC, Ewald GA, Allen LA, et al.

Journal of cardiac failure 2015; (21(6)):519-34.

Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).

Lala A, McNulty SE, Mentz RJ, et al.

Circulation. Heart failure 2015; (8(4)):741-8 doi:10.1161/CIRCHEARTFAILURE.114.001957.

Diagnostic Accuracy of Cardiac Magnetic Resonance Imaging in the Evaluation of Newly Diagnosed Heart Failure With Reduced Left Ventricular Ejection Fraction.

Won E, Donnino R, Srichai MB, et al.

The American journal of cardiology 2015; (116(7)):1082-7.

Management of Patients Admitted with Acute Decompensated Heart Failure.

Krim SR, Campbell PT, Desai S, et al.

Ochsner journal 2015; (15(3)):284-9.

Cognitive Behavior Therapy for Depression and Self-Care in Heart Failure Patients: A Randomized Clinical Trial.

Freedland KE, Carney RM, Rich MW, et al.

JAMA internal medicine 2015; (175(11)):1773-82 doi:10.1001/jamainternmed.2015.5220.

Advanced Heart Failure: Prevalence, Natural History, and Prognosis.

Chaudhry SP, Stewart GC

Heart failure clinics 2016; (12(3)):323-33.

Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.

Okumura N, Jhund PS, Gong J, et al.

Circulation. Heart failure 2016; (9(9)).

Neurohormonal activation in heart failure with reduced ejection fraction.

Hartupee J, Mann DL

Nature reviews. Cardiology 2017; (14(1)):30-38 doi:10.1038/nrcardio.2016.163.

Mechanical circulatory support for end-stage heart failure.

Combes A

Metabolism: clinical and experimental 2017; (69S()):S30-S35 doi:10.1016/j.metabol.2017.01.009.

Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes.

Gustafsson F, Rogers JG

European journal of heart failure 2017; (19(5)):595-602 doi:10.1002/ejhf.779.

Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.

Rodgers JE

The American journal of medicine 2017; (130(6)):635-639 doi:10.1016/j.amjmed.2017.02.010.

True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis.

Vukadinović D, Lavall D, Vukadinović AN, et al.

American heart journal 2017; (188()):99-108 doi:10.1016/j.ahj.2017.03.011.

Heart failure with reduced ejection fraction.

Bloom MW, Greenberg B, Jaarsma T, et al.

Nature reviews. Disease primers 2017; (3()):17058 doi:10.1038/nrdp.2017.58.

Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization.

Groarke JD, Stevens SR, Mentz RJ, et al.

Journal of cardiac failure 2018; (24(9)):542-549 doi:10.1016/j.cardfail.2017.12.013.

New Medications in the Treatment of Acute Decompensated Heart Failure.

Dahn R, Walker S

Hospital pharmacy 2018; (53(2)):85-87 doi:10.1177/0018578717750096.

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.

Damman K, Gori M, Claggett B, et al.

JACC. Heart failure 2018; (6(6)):489-498 doi:10.1016/j.jchf.2018.02.004.

Longitudinal evaluation of ventricular ejection fraction and NT-proBNP across heart failure subgroups.

Martinsson A, Oest P, Wiborg MB, et al.

Scandinavian cardiovascular journal : SCJ 2018; (52(4)):205-210 doi:10.1080/14017431.2018.1461920.

Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides?

Modin D, Andersen DM, Biering-Sørensen T

Echo research and practice 2018; (5(2)):R65-R79.

Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology.

Crespo-Leiro MG, Metra M, Lund LH, et al.

European journal of heart failure 2018; (20(11)):1505-1535 doi:10.1002/ejhf.1236.

Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.

Greene SJ, Butler J, Albert NM, et al.

Journal of the American College of Cardiology 2018; (72(4)):351-366 doi:10.1016/j.jacc.2018.04.070.

Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction.

Benfari G, Antoine C, Miller WL, et al.

Circulation 2019; (140(3)):196-206 doi:10.1161/CIRCULATIONAHA.118.038946.

Patient Selection for Destination LVAD Therapy: Predicting Success in the Short and Long Term.

Michaels A, Cowger J

Current heart failure reports 2019; (16(5)):140-149 doi:10.1007/s11897-019-00434-1.

Acute Kidney Injury, Heart Failure, and Health Outcomes.

Gudsoorkar PS, Thakar CV

Cardiology clinics 2019; (37(3)):297-305 doi:10.1016/j.ccl.2019.04.005.

Clinical profile and one-year survival of patients with heart failure with reduced ejection fraction: The largest report from India.

Chopra VK, Mittal S, Bansal M, et al.

Indian heart journal 2019; (71(3)):242-248 doi:10.1016/j.ihj.2019.07.008.

[Heart failure in old age : Current recommendations in view of the revised national treatment guidelines on chronic heart failure].

Lambrecht A, Hardt R

Zeitschrift fur Gerontologie und Geriatrie 2019; (52(7)):701-712 doi:10.1007/s00391-019-01617-0.

Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.

Rørth R, Jhund PS, Yilmaz MB, et al.

Circulation. Heart failure 2020; (13(2)):e006541 doi:10.1161/CIRCHEARTFAILURE.119.006541.

Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients.

Cautela J, Tartiere JM, Cohen-Solal A, et al.

European journal of heart failure 2020; (22(8)):1357-1365 doi:10.1002/ejhf.1835.

Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.

Vaduganathan M, Claggett BL, Jhund PS, et al.

Lancet (London, England) 2020; (396(10244)):121-128 doi:10.1016/S0140-6736(20)30748-0.

Inpatient Initiation of Sacubitril/Valsartan.

Chilbert MR, Rogers KC, Ciriello DN, et al.

The Annals of pharmacotherapy 2021; (55(4)):480-495 doi:10.1177/1060028020947446.

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

Zannad F, Ferreira JP, Pocock SJ, et al.

Lancet (London, England) 2020; (396(10254)):819-829 doi:10.1016/S0140-6736(20)31824-9.

Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.

Ibrahim NE, Piña IL, Camacho A, et al.

European journal of heart failure 2020; (22(11)):2018-2025 doi:10.1002/ejhf.2005.

A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy.

De Vecchis R, Paccone A

SAGE open medical case reports 2020; (8()):2050313X20952189 doi:10.1177/2050313X20952189.

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?

Khan MS, Vaduganathan M

Current diabetes reports 2020; (20(11)):63 doi:10.1007/s11892-020-01347-3.

The Benefit of Atrioventricular Junction Ablation for Permanent Atrial Fibrillation and Heart Failure Patients Receiving Cardiac Resynchronization Therapy: An Updated Systematic Review and Meta-analysis.

Waranugraha Y, Rizal A, Setiawan D, Aziz IJ

Indian pacing and electrophysiology journal 2021; (21(2)):101-111 doi:10.1016/j.ipej.2020.12.005.

The Optimal Timing of Primary Prevention Implantable Cardioverter-Defibrillator Referral in the Rapidly Changing Medical Landscape.

Wong JA, Roberts JD, Healey JS

The Canadian journal of cardiology 2021; (37(4)):644-654 doi:10.1016/j.cjca.2021.01.024.

Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.

Bozkurt B, Coats AJS, Tsutsui H, et al.

European journal of heart failure 2021; (23(3)):352-380 doi:10.1002/ejhf.2115.

Universal Definition and Classification of Heart Failure.

Bozkurt B, Coats A, Tsutsui H

Journal of cardiac failure 2021; doi:10.1016/j.cardfail.2021.01.022.

Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper.

Silva-Cardoso J, Fonseca C, Franco F, et al.

Revista portuguesa de cardiologia 2021; doi:10.1016/j.repc.2021.07.009.

Treatment of Advanced Heart Failure-Focus on Transplantation and Durable Mechanical Circulatory Support: What Does the Future Hold?

Guidetti F, Arrigo M, Frank M, et al.

Heart failure clinics 2021; (17(4)):697-708 doi:10.1016/j.hfc.2021.05.013.

Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy.

Rahamim E, Nachman D, Yagel O, et al.

Journal of clinical medicine 2021; (10(19)) doi:10.3390/jcm10194409.

Heart failure with mildly reduced ejection fraction: emerging frontiers in clinical characteristics, prognosis, and treatment.

Shang Z, Wang X, Gao W

Reviews in cardiovascular medicine 2022; (23(1)):30 doi:10.31083/j.rcm2301030.

Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.

Beldhuis IE, Lam CSP, Testani JM, et al.

Circulation 2022; (145(9)):693-712 doi:10.1161/CIRCULATIONAHA.121.052792.

Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.

Mullens W, Martens P, Testani JM, et al.

European journal of heart failure 2022; (24(4)):603-619 doi:10.1002/ejhf.2471.

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Heidenreich PA, Bozkurt B, Aguilar D, et al.

Journal of the American College of Cardiology 2022; (79(17)):1757-1780 doi:10.1016/j.jacc.2021.12.011.

Foundational drugs for HFrEF: the growing evidence for a rapid sequencing strategy.

Docherty KF, McMurray JJV

The British journal of cardiology 2022; (29(1)):2 doi:10.5837/bjc.2022.002.

Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?

Abdelhamid M, Rosano G, Metra M, et al.

European journal of heart failure 2022; (24(9)):1460-1466 doi:10.1002/ejhf.2594.

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.

Butler J, Anker SD, Lund LH, et al.

European heart journal 2022; (43(41)):4362-4373 doi:10.1093/eurheartj/ehac401.

Consensus statement on the current pharmacological prevention and management of heart failure.

Sindone AP, De Pasquale C, Amerena J, et al.

The Medical journal of Australia 2022; (217(4)):212-217 doi:10.5694/mja2.51656.

Edema formation in congestive heart failure and the underlying mechanisms.

Abassi Z, Khoury EE, Karram T, Aronson D

Frontiers in cardiovascular medicine 2022; (9()):933215 doi:10.3389/fcvm.2022.933215.

Why Do so Few People with Heart Failure Receive Cardiac Rehabilitation?

Thompson DR, Ski CF, Clark AM, et al.

Cardiac failure review 2022; (8()):e28 doi:10.15420/cfr.2022.16.

Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials.

Friedman DJ, Al-Khatib SM, Dalgaard F, et al.

Circulation 2023; (147(10)):812-823 doi:10.1161/CIRCULATIONAHA.122.062124.

Left ventricular assist device implantation and clinical outcomes in the Netherlands.

Damman K, Caliskan K, Birim O, et al.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2023; (31(5)):189-195 doi:10.1007/s12471-023-01760-9.

Misconceptions and Facts about Heart Failure with Reduced Ejection Fraction.

Krittanawong C, Rodriguez M, Lui M, et al.

The American journal of medicine 2023; (136(5)):422-431 doi:10.1016/j.amjmed.2023.01.024.

Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.

Malgie J, Clephas PRD, Brunner-La Rocca HP, et al.

Heart failure reviews 2023; (28(5)):1221-1234 doi:10.1007/s10741-023-10325-2.

Treatment of depression and inadequate self-care in patients with heart failure: One-year outcomes of a randomized controlled trial.

Freedland KE, Skala JA, Carney RM, et al.

General hospital psychiatry 2023; (84()):82-88 doi:10.1016/j.genhosppsych.2023.06.001.

Heart Failure Management in 2023: A Pharmacotherapy- and Lifestyle-Focused Comparison of Current International Guidelines.

MacDonald BJ, Virani SA, Zieroth S, Turgeon R

CJC open 2023; (5(8)):629-640 doi:10.1016/j.cjco.2023.05.008.

Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?

Hu JR, Schwann AN, Tan JW, et al.

Cardiology clinics 2023; (41(4)):511-524 doi:10.1016/j.ccl.2023.06.007.

Tailoring guideline-directed medical therapy in heart failure with reduced ejection fraction: A practical guide.

Kapłon-Cieślicka A, Vardas P, Grabowski M, Lelonek M

Kardiologia polska 2023; (81(9)):850-858 doi:10.33963/v.kp.97062.

Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS).

Maryam , Varghese TP, B T

Current problems in cardiology 2024; (49(4)):102411 doi:10.1016/j.cpcardiol.2024.102411.

Exercise-based cardiac rehabilitation for adults with heart failure.

Molloy C, Long L, Mordi IR, et al.

The Cochrane database of systematic reviews 2024; (3()):CD003331 doi:10.1002/14651858.CD003331.pub6.

Multidisciplinary approach to long-standing left bundle branch block with dyssynchrony and aortic stenosis: case report.

Maigrot JA, Weiss AJ, Wazni O, Starling RC

European heart journal. Case reports 2024; (8(4)):ytae127 doi:10.1093/ehjcr/ytae127.

Heart failure management with β-blockers: can we do better?

de Oliveira MT, Baptista R, Chavez-Leal SA, Bonatto MG

Current medical research and opinion 2024; (40(sup1)):43-54 doi:10.1080/03007995.2024.2318002.

Longitudinal NT-proBNP: Associations With Echocardiographic Changes and Outcomes in Heart Failure.

Teramoto K, Tay WT, Tromp J, et al.

Journal of the American Heart Association 2024; (13(9)):e032254 doi:10.1161/JAHA.123.032254.

Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study.

Veltmann C, Duncker D, Doering M, et al.

European heart journal 2024; (45(30)):2771-2781 doi:10.1093/eurheartj/ehae334.

Full decongestion in acute heart failure therapy.

Buttar C, Alai H, Matanes FN, et al.

The American journal of the medical sciences 2024; (368(3)):182-189 doi:10.1016/j.amjms.2024.06.002.

2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures.

, Kittleson MM, Breathett K, et al.

Journal of the American College of Cardiology 2024; (84(12)):1123-1143 doi:10.1016/j.jacc.2024.05.014.

Long-term follow-up of the TRED-HF trial: Implications for therapy in patients with dilated cardiomyopathy and heart failure remission.

Cheng L, Hammersley D, Ragavan A, et al.

European journal of heart failure 2025; (27(1)):113-123 doi:10.1002/ejhf.3475.

Guidelines for treating heart failure.

Kittleson MM

Trends in cardiovascular medicine 2025; (35(3)):141-150 doi:10.1016/j.tcm.2024.10.002.

Survival and Readmission Burden in Advanced Heart Failure Patients Managed With Ventricular Assist Device Versus Continued Medical Therapy.

Alexis JD, Wood K, Gosev I, et al.

ASAIO journal (American Society for Artificial Internal Organs : 1992) 2025; (71(8)):628-636 doi:10.1097/MAT.0000000000002382.

Management of Heart Failure With Improved Ejection Fraction: Current Evidence and Controversies.

Kodur N, Tang WHW

JACC. Heart failure 2025; (13(4)):537-553 doi:10.1016/j.jchf.2025.02.007.

Who is the Candidate? The Heart Transplant Evaluation Process.

Kittleson MM

Methodist DeBakey cardiovascular journal 2025; (21(3)):13-24 doi:10.14797/mdcvj.1512.

Factors Predicting Myocardial Recovery After Hospitalization for De Novo Heart Failure with Reduced Left Ventricular Ejection Fraction: Results from the COMFE Registry.

Donoso-Trenado V, Otero-García Ó, López-Vilella R, et al.

Biomedicines 2025; (13(5)) doi:10.3390/biomedicines13051143.

Impact of home-based cardiac rehabilitation in people with heart failure with elevated depressive and anxiety symptoms: a secondary analysis of the REACH-HF randomized trials.

Lambert J, Dibben G, van Beurden SB, et al.

European journal of cardiovascular nursing 2026; (25(1)):186-192 doi:10.1093/eurjcn/zvaf196.

N‑Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) as a Biomarker in Heart Failure With Preserved Ejection Fraction (HFpEF) Versus Heart Failure With Reduced Ejection Fraction (HFrEF): The Way Forward in the Age of Proteomics.

Kanyal S, Das A, Bashir AMD, et al.

Cureus 2025; (17(10)):e94162 doi:10.7759/cureus.94162.

Heart failure with reduced ejection fraction.

Cannata A, Crespo-Leiro MG, Bromage DI, et al.

Lancet (London, England) 2026; (407(10527)):529-542 doi:10.1016/S0140-6736(25)01851-3.

Hormonal crossroads of the heart: from classic endocrine regulation to cardiac hormone secretion: an updated review.

Iglesias P, Iglesias I

Journal of endocrinological investigation 2026; (49(4)):747-761 doi:10.1007/s40618-025-02767-2.

Prognostic significance of subsequent decline in LVEF in heart failure with improved ejection fraction - A report from the CHART-2 study.

Takigahira T, Nochioka K, Miyata S, et al.

International journal of cardiology. Heart & vasculature 2026; (62()):101877 doi:10.1016/j.ijcha.2026.101877.

European Journal of Heart Failure International Expert Position Paper-Utilization, optimization, and clinical benefits of steroidal mineralocorticoid receptor antagonists in heart failure with a reduced ejection fraction.

Böhm M, Abdullakutty J, Bauersachs J, et al.

European journal of heart failure 2026; (28(3)):513-534 doi:10.1093/ejhf/xuag106.

State-of-the-art management of ischemic cardiomyopathy: integrating diagnostic pathways, revascularization strategies, and guideline-directed therapy.

Busti M, Melenovsky V, Savarese G, et al.

Heart failure reviews 2026; (31(1)).

[Cardiovascular magnetic resonance imaging: routine use in cardiology and unique strengths].

Schulz A, Reiter T

Innere Medizin (Heidelberg, Germany) 2026; doi:10.1007/s00108-026-02152-y.

Natriuretic Peptides as Predictors for the Diagnosis of Pulmonary Hypertension Secondary to Left Heart Disease and for the Assessment of Its Severity.

Sawczak F, Kukfisz A, Soloch A, et al.

International journal of molecular sciences 2026; (27(17)) doi:10.3390/ijms27177776.